华兰疫苗
(301207)
| 流通市值：30.01亿 | | | 总市值：127.68亿 |
| 流通股本：1.41亿 | | | 总股本：6.00亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 623,990,420.48 | 640,980,111.95 | 375,780,768.04 | 734,259,178.99 |
| 应收票据及应收账款 | 1,576,861,211.76 | 1,990,499,738.65 | 2,083,044,517.86 | 1,000,649,830.06 |
| 应收账款 | 1,576,861,211.76 | 1,990,499,738.65 | 2,083,044,517.86 | 1,000,649,830.06 |
| 预付款项 | 43,895,757.12 | 28,180,812.22 | 28,735,183.66 | 24,930,223.29 |
| 其他应收款合计 | 2,561,251.77 | 1,311,830.95 | 3,651,019.84 | 4,001,020.93 |
| 存货 | 321,521,477.26 | 173,470,942.08 | 291,551,265.8 | 425,543,840.13 |
| 一年内到期的非流动资产 | 346,805,555.56 | 373,457,527.79 | 371,298,083.33 | 369,138,638.89 |
| 其他流动资产 | - | 420,390,306.25 | - | 15,930,189.74 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 5,313,164,810.94 | 5,226,815,305.37 | 5,041,192,871.31 | 4,005,190,983.63 |
| 非流动资产: | | | | |
| 固定资产 | 1,144,765,707.5 | 1,171,557,110.64 | 1,204,003,175.41 | 1,227,968,080.07 |
| 在建工程 | 4,092,452 | 3,228,452 | 3,297,915.22 | 3,297,915.22 |
| 生产性生物资产 | 367,153.15 | 965,100.05 | 1,569,901.71 | 349,001.83 |
| 无形资产 | 19,963,039.13 | 20,126,224.73 | 20,289,410.33 | 20,452,595.93 |
| 开发支出 | 26,915,859.53 | 26,269,230.64 | 25,772,432.17 | 25,021,768.89 |
| 长期待摊费用 | 1,251,943.44 | 1,669,257.93 | - | 1,473,300.07 |
| 递延所得税资产 | 212,590,324.26 | 217,969,365.85 | 209,377,033.6 | 200,276,678.94 |
| 其他非流动资产 | 1,086,065,175.63 | 1,326,718,250 | 1,302,366,666.78 | 1,306,947,054.54 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,496,011,654.64 | 2,768,502,991.84 | 2,766,676,535.22 | 2,785,786,395.49 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,809,176,465.58 | 7,995,318,297.21 | 7,807,869,406.53 | 6,790,977,379.12 |
| 流动负债: | | | | |
| 短期借款 | 300,000,000 | 300,183,333.33 | 300,000,000 | 300,000,000 |
| 应付票据及应付账款 | 142,908,189.43 | 116,759,651.63 | 122,072,715.81 | 135,215,845.08 |
| 其中：应付票据 | 19,863,430 | - | 3,130,000 | 18,512,440 |
| 应付账款 | 123,044,759.43 | 116,759,651.63 | 118,942,715.81 | 116,703,405.08 |
| 合同负债 | 6,866,784.94 | 2,671,416.5 | 6,177,678.15 | 4,599,431.03 |
| 应付职工薪酬 | 45,385.55 | - | - | 3,542.67 |
| 应交税费 | 2,290,880.72 | 57,681,536.63 | 84,202,901.89 | 2,474,692.54 |
| 其他应付款合计 | 1,004,722,672.07 | 1,208,206,691.55 | 1,221,028,472.43 | 805,419,611.09 |
| 其他流动负债 | 205,916.01 | 80,086.45 | 185,284.8 | 137,843.79 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,457,039,828.72 | 1,685,582,716.09 | 1,733,667,053.08 | 1,247,850,966.2 |
| 非流动负债: | | | | |
| 递延收益 | 30,363,607.84 | 31,422,151.5 | 32,480,695.16 | 33,539,238.82 |
| 递延所得税负债 | 14,561,322.29 | 15,221,503.2 | 13,828,141.82 | 10,390,538.25 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 44,924,930.13 | 46,643,654.7 | 46,308,836.98 | 43,929,777.07 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,501,964,758.85 | 1,732,226,370.79 | 1,779,975,890.06 | 1,291,780,743.27 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 600,015,000 | 600,015,000 | 600,015,000 | 600,015,000 |
| 资本公积 | 2,920,707,131.72 | 2,915,176,814.79 | 2,910,232,165.78 | 2,903,030,382.6 |
| 盈余公积 | 286,156,631.76 | 286,156,631.76 | 200,005,000 | 200,005,000 |
| 未分配利润 | 2,500,332,943.25 | 2,461,743,479.87 | 2,317,641,350.69 | 1,796,146,253.25 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 6,307,211,706.73 | 6,263,091,926.42 | 6,027,893,516.47 | 5,499,196,635.85 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 6,307,211,706.73 | 6,263,091,926.42 | 6,027,893,516.47 | 5,499,196,635.85 |
| 负债和股东权益合计 | 7,809,176,465.58 | 7,995,318,297.21 | 7,807,869,406.53 | 6,790,977,379.12 |
| 公告日期 | 2024-04-26 | 2024-03-30 | 2023-10-28 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |